Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels.
Journal
Advances in urology
ISSN: 1687-6369
Titre abrégé: Adv Urol
Pays: Egypt
ID NLM: 101476240
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
03
2019
accepted:
09
09
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
11
2019
Statut:
epublish
Résumé
Both elevated testosterone and polycystic ovary syndrome (PCOS) have been speculated as possible risk factors for kidney stone formation; however, the details of this potential relationship with regards to 24-hour urine metabolic panels and stone composition have not previously been characterized. A total of 74 PCOS patients were retrospectively identified and matched with a cohort of female stone formers at a 3 : 1 ratio (by age and BMI). All patients had 24-hour urinary metabolic panels and stone compositions. These groups were compared using Pearson chi-square and Student The case-control cohort showed that PCOS patients had significantly lower sodium excretion ( Compared to healthy stone formers, PCOS patients did not demonstrate significant differences in 24-hour urine and stone composition values. Elevated free testosterone in PCOS patients has a significant association with higher urinary citrate and sodium values: findings that in and of themselves do not confirm the hypothesized increased risk of stone formation. This patient cohort may provide deeper insight into the interplay between androgens and stone formation; however, further study is needed to fully characterize the possible relationship between PCOS and stone formation.
Identifiants
pubmed: 31772573
doi: 10.1155/2019/3679493
pmc: PMC6854272
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3679493Informations de copyright
Copyright © 2019 Donald Fedrigon III et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Fertil Steril. 2002 Sep;78(3):569-76
pubmed: 12215335
Fertil Steril. 2009 Feb;91(2):456-88
pubmed: 18950759
Int J Appl Basic Med Res. 2016 Oct-Dec;6(4):241-244
pubmed: 27857889
J Urol. 2010 Feb;183(2):571-5
pubmed: 20018330
J Clin Endocrinol Metab. 2003 Dec;88(12):5907-13
pubmed: 14671189
J Clin Endocrinol Metab. 2006 Nov;91(11):4395-400
pubmed: 16940454
JAMA. 2005 Jan 26;293(4):455-62
pubmed: 15671430
Rev Urol. 2010 Fall;12(4):e157-80
pubmed: 21234260
J Clin Endocrinol Metab. 2006 Jan;91(1):48-53
pubmed: 16249284
Lancet. 2006 Jan 28;367(9507):333-44
pubmed: 16443041
Arch Ital Urol Androl. 2015 Mar 31;87(1):83-6
pubmed: 25847904
J Endourol. 2010 Jul;24(7):1183-7
pubmed: 20590469
Endocrine. 2006 Aug;30(1):13-7
pubmed: 17185787
J Urol. 1996 Aug;156(2 Pt 1):502-5
pubmed: 8683725
Hypertension. 2007 Jun;49(6):1442-7
pubmed: 17389259
Clin Exp Pharmacol Physiol. 1999 Feb;26(2):127-31
pubmed: 10065333
Urol Clin North Am. 2007 Aug;34(3):287-93
pubmed: 17678980
J Endourol. 2015 Dec;29(12):1341-5
pubmed: 26422682
Kidney Int. 2003 May;63(5):1817-23
pubmed: 12675858
Trends Endocrinol Metab. 2007 Sep;18(7):266-72
pubmed: 17693095
J Appl Physiol (1985). 2001 Oct;91(4):1893-901
pubmed: 11568177
Hypertension. 2014 Mar;63(3):624-9
pubmed: 24324038
PLoS One. 2014 Apr 02;9(4):e93790
pubmed: 24695421
Urolithiasis. 2013 Aug;41(4):361-2
pubmed: 23604095
Fertil Steril. 2006 Jul;86 Suppl 1:S18-9
pubmed: 16798277
J Sex Med. 2011 Oct;8(10):2924-34
pubmed: 21771278